Earnings Feed
Start Free
Home/Filings/4/0001780660-26-000003
4//SEC Filing

LO FRANCIS 4

Accession 0001780660-26-000003

CIK 0001478320other
View on SEC.govCompany Profile

Filed

Jan 13, 7:00 PM ET

Accepted

Jan 14, 7:42 PM ET

Size

21.1 KB

Accession

0001780660-26-000003

Insider Transaction Report

Form 4
Period: 2026-01-12
Adaptive Biotechnologies CorpADPT
LO FRANCIS
Chief People Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-01-12$7.80/sh+36,650$285,870→ 352,628 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-01-12$12.14/sh+7,723$93,757→ 360,351 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-01-12$8.46/sh+21,002$177,677→ 381,353 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-01-12$3.99/sh+14,215$56,718→ 395,568 total
  • Sale

    Common Stock

    [F1]
    2026-01-12$17.73/sh−79,590$1,411,131→ 315,978 total
  • Exercise/Conversion

    Stock Option (right to buy)

    [F1][F2]
    2026-01-12−36,650→ 75,500 total
    Exercise: $7.80Exp: 2029-05-06→ Common Stock (36,650 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    [F1][F3]
    2026-01-12−7,723→ 177,615 total
    Exercise: $12.14Exp: 2032-03-04→ Common Stock (7,723 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    [F1][F4]
    2026-01-12−21,002→ 87,074 total
    Exercise: $8.46Exp: 2033-03-06→ Common Stock (21,002 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    [F1][F5]
    2026-01-12−14,215→ 90,641 total
    Exercise: $3.99Exp: 2034-03-04→ Common Stock (14,215 underlying)
Holdings

  • Common Stock

    (indirect: By Spouse)
    2,500
Footnotes (5)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
  • [F2]The option is fully vested and exercisable.
  • [F3]The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  • [F4]The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  • [F5]The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Signature
/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact|2026-01-14

Documents

1 file

Issuer

Adaptive Biotechnologies Corp

CIK 0001478320

→
Entity typeother

Related Parties

1
  • filerCIK 0001780660

Filing Metadata

Form type
4
Filed
Jan 13, 7:00 PM ET
Accepted
Jan 14, 7:42 PM ET
Size
21.1 KB
View on SEC.gov